Data recovery and integration from public databases uncovers transformation-specific transcriptional downregulation of cAMP-PKA pathway-encoding genes

Table 5 NCI60 cell lines with predicted active pathways by mutational analysis

Tumor Type	Ras	PI3K	Other Mutation	Not Tested
Breast	HS578T, MDA-MB231, MD-MB435	MCF7, T47,	-	MDA-N, BT549
CNS	-	SF295, SF359, SNB19, U251	SF268, SNB75	-
Colon	HCC2998, HCT116, HCT15, SW620, COLO205, HT29	KM12	-	-
Leukaemia	CCRF-CEM, RPMI-8226, HL60, MOLT4, K562	-	-	SR
Melanoma	SK-MEL2, LOXIMVI, M14, MALME-3M, SK-MEL28, SK-MEL5, UACC257, UACC62	-	-	-
Lung	A549, HOP62, NCI-H23, NCI-H460	-	EKVX, NCI-H226, NCI-H322, NCI-H522	HOP92
Ovarian	OVCAR5, OVCAR8	SKOW3, IGROV1	OVCAR3, OVCAR4	-
Prostate	-	PC3, DU145	-	-
Renal	-	786-0, RXF-393	A498, ACHN, CAKI-1, SNC12C, TK10, U031	-
Unknown	ADR-RES	-	-	-

The 60 cell lines reorganized in 4 categories, as described in the text, on the basis of the most representative mutation of each cell line:
Cell lines carrying mutations able to interfere with Ras-Raf-MAPK pathway (i.e., mutations in genes encoding Ras, B-Raf, ERBB2, PDGFRA, referred to as Ras);
Cell lines carrying mutations able to interfere with PI3K-Akt pathway (i.e., mutations in genes encoding PI3KCA, PTEN and Lkb1, referred to as PI3K);
Cell lines carrying no somatic mutations interfering with the two above pathways (i.e., mutations in genes encoding for CDKN2A, p53, referred to as Other Mutation);
Cell lines for which the presence of somatic mutations interfering with the two above pathways has not been searched, referred to as Not Tested.

ISSN: 1471-2105